Introduction
in spite of undeniable contributions to the field of mental health, psychopharmacological research is coming more and more under attack by various human rights groups and for different reasons. Such attacks are already bringing much pressure on existing psychiatric drug research and in some cases have halted it completely (7) .
Psychopharmacological research obviously needs to be pursued for two main reasons. First, new, more specific drugs are required for schizophrenic and geriatric patients who are still chronically distressed, dysphoric and non-functional despite our unceasing efforts in providing them with the best psychopharmacotherapy possible, and in utilizing optimally psychosocial therapies (7) . Secondly, current psychotropic drugs are not completely devoid of side effects whose importance varies in degrees. With respect to tardive dyskinesia, a neurological condition often irreversible and associated with the administration of neuroleptics, the medical and legal implications are serious. Although a considerable amount of basic and clinical research has been done no markedly effective treatment for this side effect has yet been found. Excellent comprehensive reviews have been written concerning the different facets of this neurological complication (4, 18, 21) and recently a special section of the American Journal of Psychiatry has been devoted to the subject (2 
Search for Treatment
Tardive dyskinesia, although a neurological condition, has attracted the interest of neurologists later than that of psychiatrists. Basic and clinical researchers in the field of the extrapyramidal system, previously involved in the study of nondrug-induced extrapyramidal manifestations, particularly Parkinson's disease, are also now sharing this interest. The search for a treatment of tardive dyskinesia has generally been guided by the putative biochemical mechanisms underlying the extrapyramidal functioning.
A currently postulated mechanism in tardive dyskinesia involves, namely, an imbalance between the central dopamineacetylcholine systems. The development of denervation or of disuse supersensitivity of dopamine receptors (4, 15, 16, 21) , of dopaminergic overactivity (23) , could contribute to this imbalance. Neuroendocrine factors, such as hormones (estrogens) can also be an influence (5, 30) . Furthermore, it has been hypothesized that striatal dopamine receptors respond differently at various stages of striatal dysfunction (6) .
Various pharmacological agents act differently on tardive dyskinesia, either suppressing or decreasing it, worsening it, or showing variable, negligible or uncertain effects (4) . The drugs that can bring about some improvement fall into the categories of dopamine antagonists, amine-depleting. agents, blockers of catecholamine synthesis or release, cholinergic agents and GABA-agonists. Those aggravating it consist of anticholinergic agents and dopamine agonists. As the differential pharmacology of tardive dyskinesia is almost the opposite of that of parkinsonism, it is understandable that the effect of these agents on this condition is contrary to their effect on parkinsonism.
The use of neuroleptics for the treatment of tardive dyskinesia is a fallacy because the agent used for treatment is the causative one and a vicious circle is thus created. Neuroleptics can temporarily mask the dyskinesia, but finally will most likely aggravate it, leading possibly to the administration of higher and higher doses of a neuroleptic to control it (29) .
Coexistence of Various Extrapyramidal Symptoms
Tardive dyskinesia and drug-induced parkinsonism can coexist (23) and this requires further elucidation. In patients treated with neuroleptics, parkinson-like symptoms and tardive dyskinesia can indeed be observed together. During the experimental treatment of tardive dyskinesia, some improvement can occur without apparent modification of the former symptoms (23) . Release phenomena can also be present and remain unmodified (23) . Moreover, in the treatment of tardive dyskinesia with reserpine, a dynamic fluctuation in the oral symptomatology can occur. Indeed, an oral dyskinesia relieved by this treatment was replaced transitorily, once reserpine had been withdrawn and the neuroleptic medication continued, by the rabbit syndrome (25) which in turn was replaced by tardive dyskinesia (24) .
In our polygraphic studies conducted during sleep and wakefulness (13, 27) , it has been observed that tardive dyskinesia and the rabbit syndrome, both involving the oral region and not mutually exclusive, appear to possess different und~rlying mechanisms. Apart from its persistence during NREM stage I of sleep where tardive dyskinesia is absent, the rabbit syndrome consistently increases in intensity during attention concentration and performance of a motor task. Antiparkinsonian drugs, beneficial in various degrees for the treatment of the rabbit syndrome, are not effective in tardive dyskinesia and even worsen it.
Therapeutic Trials
The study of agents potentially effective for the treatment of tardive dyskinesia is laborious and presents many pitfalls. The unpredictability of results in the therapeutic trials in this condition might be caused by the interplay of three main groups: I. Patient variables 2. Experimental treatment variables 3. Methodological variables
Patient Variables
A genetic predisposition to neurolepticinduced extrapyramidal impairment and its relationship with the irreversibility of tardive dyskinesia is difficult to evaluate.
The fact that the occurrence of tardive .dyskinesia increases steadily with age (50 years and over) should lead to the exploration ofthe influence ofneuroendocrine changes (5, 30) , associated with aging, on biogenic amines mod ulating the activity of the extrapyramidal system. Similarly, investigations should continue on the enzymatic changes which occur during senescence (17, 20) and also on the interplay of disinhibitory influences (release phenomena) with tardive dyskinesia (28) .
It is known that movement disorders in schizophrenia sometimes resemble extrapyramidal disorders, but they can usually be differentiated from tardive dyskinesia (18) . Iterative activities (including oral movements) and release phenomena' in psychogeriatric patients suffering from an organic brain syndrome and treated with neuroleptics have been reported to differ notably from a control group (28) . The combination of non-drug-induced oral dyskinesia in aged patients and of edentulism can also increase the intensity of a neuroleptic-induced oral dyskinesia, as well as drug-induced dryness of the mouth.
All this may account for an important variability in experimental results and patients of different age groups may also respond differently to the experimental treatment. The significance of nutritional factors (II) in long-term institutionalized patients is also difficult to assess.
Several physiological factors can also modify the intensity of tardive dyskinesia which progressively decreases with the diminution of vigilance and disappears during sleep, and which increases with emotional tension, fatigue or performance of a motor task, for example, the labyrinth test (23) . Indeed, some pharmacological agents may produce improvement by decreasing vigilance (14) and some dyskinesias become apparent only when patients are asked to perform certain activities in remote groups of muscles. Voluntary movements seem therefore to exert a fly-wheel effect in that they increase hyperkinesia in remote groups of muscles (8) . Concentration and performance of a motor task test can be useful in distracting those patients who self-consciously limit their dyskinetic movements during rating.
Finally, the impossibility of knowing if a tardive dyskinesia is still in a stage of reversibility complicates the assessment of the comparative efficacy of pharmacological agents. Whether the neuroleptic medication is interrupted or not, if a very marked dyskinesia is chosen, it may already be irreversible and the treatment may appear ineffective while in fact it is not. On the contrary, if the dyskinesia is mild, it may be too labile and still reversible leading to belief in the efficacy or the superiority of a given drug.
Experimental Treatment Variables
The chances of a treatment to be effective depend largely on the validity of the underlying biochemical hypothesis is an aphorism. Assuming the correctness of the hypothesis of a mere imbalance between the striatal dopamine and acetylcholine systems, it might be wiser to add a second experimental drug that could act on the other side of the balance if the first drug showed little or no effectiveness. Thus, such a combination of drugs might be effective.
Insufficient length of treatment and/ or inadequate dosage, as well as neuroleptictreatment interference, are also variables that can influence the therapeutic results. If the neuroleptics are withdrawn, there is the prospect of either spontaneous worsening or improvement of the tardive dyskinesia and, from a psychological standpoint, the possible occurrence of a psychotic relapse necessitating the resumption of the neuroleptic treatment. On the other hand, if the neuroleptic medication is maintained, its interference with the experimental drug treatment renders more complex the evaluation of its effect.
Finally, another parameter complicating the assessment of a putative therapeutic agent is the influence of the metabolic interactions already existing with the psychotropic medication administered (metabolic interactions between neuroleptics and antiparkinsonians, between neuroleptics and tricyclic antidepressants) and the consequent enzymatic system changes.
Methodological Variables
Over the years, our methodology of psychotropic drug trials has become more and more sophisticated. Unfortunately, a survey of the abundant literature devoted to the experimental treatment of tardive dyskinesia reveals that few studies, except in recent years, have shown a deep concern for scientifically sound trial designs. A large number of reports are indeed anecdotal, some involve a single case and others include a few, usually treated for brief periods. There is a paucity of controlled, comparative, double-blind trials. The intensive design, that is, the study of a small number of cases over extended periods of time (a year or more) with different experimental drug treatment, seems to have been a neglected approach.
Even though the design of a trial may respond to all the adequate methodological criteria, the measuring devices must also possess reliability (including interrater reliability), validity, sensitivity and replicability. Besides clinical rating scales (19, 22) , teaching movies (3, 12, 26) and videotapes (9) , various instrumental techniques have already been devised for the investigation of tardive dyskinesia and its treatment, namely EEG coupled with EMG (13), transducer recordings (6), cineseismography (31), computerized tomography (10), tremography (I) and speech assessment (9) . However, not a single technique is satisfactory and a combination of several is preferable. Finally, it is obvious that the investigator must be familiar with the field of tardive dyskinesia and experienced and competent in the use of the various measuring devices utilized, as well as in the interpretation of the data obtained.
Conclusion
This brief survey of the numerous variables involved in the assessment of the efficacy of an experimentaldrug treatment in tardive dyskinesia shows the complexity of such an investigation. A rational therapeutic approach based on biochemical hypotheses has proven fruitful in the treatment of Parkinson's disease. The pursuit of such an approach in tardive dyskinesia, taking into account, as much as possible, the numerous variables involved and using a sound methodology, could yield interesting therapeutic leads. Finally, it should always be borne in mind that prevention is still the best therapeutic approach.
Summary
The search for a treatment of tardive dyskinesia has generally been guided by the putative biochemical mechanisms underlying the extrapyramidal disorders, but no markedly effective treatment has yet been found. The currently postulated mechanism in tardive dyskinesia involves namely an imbalance between the central dopamine-acetylcholine systems whose balance may also be influenced by neuroendocrine factors. The agents reported having some clinical efficacy in the management of this neurological complication act on these systems. The clinical investigation for the treatment of tardive dyskinesia is laborious and raises several problems that could account for the unpredictability and the discrepancies in results. These problems can be divided into three broad categories: patient variables, experimental treatment variables and methodological variables. These variables are discussed and some suggestions made.
